Abstract
Prognosis of colorectal patients with unresectable tumors or progress after standardized multimodal treatment is dismal.
The new concept of multi-targeted therapy against intrapatient genetic heterogeneity applying targeted NGS (tNGS) represents now the most rational approach to potential survival. This mini-review evaluates the clinical utility of extensive gene panel in tumoral and liquid samples.
Despite the promising data of basket trials there is need to shift from current expert’s panel decision-making treatment to randomized clinical trials to establish drug commitment for agents approved for other CRC patients having genetic detectable alterations.

(Citation: Gastric & Breast Cancer 2020; 15(1): 43-51)

Back

PDF Version